Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
  • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
  • C12N5/0659—Satellite cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/06—Anabolic agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
  • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2510/00—Genetically modified cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2533/00—Supports or coatings for cell culture, characterised by material
  • C12N2533/50—Proteins
  • C12N2533/54—Collagen; Gelatin

Definitions

• the present invention relates to muscle-derived progenitor cells (MDCs) and compositions of MDCs and their use in the augmentation of body tissues, particularly skeletal muscle.
• the present invention relates to muscle-derived progenitor cells that show long-term survival following introduction into skeletal muscle, methods of isolating MDCs and methods of using MDC-containing compositions for the augmentation of human or animal skeletal muscle.
• the invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.
• the invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
• Myoblasts the precursors of muscle fibers, are mononucleated muscle cells that fuse to form post-mitotic multinucleated myotubes, which can provide long-term expression and delivery of bioactive proteins (T. A. Partridge and K. E. Davies, 1995, Brit. Med. Bulletin 51:123 137; J. Dhawan et al, 1992, Science 254: 1509 12; A. D. Grinnell, 1994, Myology Ed 2, A. G. Engel and C. F. Armstrong, McGraw-Hill, Inc., 303 304; S. Jiao and J. A. Wolff, 1992, Brain Research 575: 143 7; H. Vandenburgh, 1996, Human Gene Therapy 7:2195 2200).
• Cultured myoblasts contain a subpopulation of cells that show some of the self- renewal properties of stem cells (A. Baroffio et al, 1996, Differentiation 60:47 57). Such cells fail to fuse to form myotubes, and do not divide unless cultured separately (A. Baroffio et al, supra).
• Studies of myoblast transplantation have shown that the majority of transplanted cells quickly die, while a minority survive and mediate new muscle formation (J. R. Beuchamp et al, 1999, J. Cell Biol. 144:1113 1122). This minority of cells shows distinctive behavior, including slow growth in tissue culture and rapid growth following transplantation, suggesting that these cells may represent myoblast stem cells (J. R.
• Myoblasts have been used as vehicles for gene therapy in the treatment of various muscle- and non-muscle-related disorders.
• transplantation of genetically modified or unmodified myoblasts has been used for the treatment of Duchenne muscular dystrophy (E. Gussoni et al, 1992, Nature, 356:435 8; J. Huard et al, 1992, Muscle & Nerve, 15:550 60; G. Karpati et al, 1993, Ann. Neurol., 34:8 17; J. P. Tremblay et al, 1993, Cell Transplantation, 2:99 112; P. A. Moisset et al, 1998, Biochem. Biophys. Res. Commun.
• myoblasts have been genetically engineered to produce proinsulin for the treatment of Type 1 diabetes (L. Gros et al, 1999, Hum. Gen. Ther. 10:1207 17); Factor IX for the treatment of hemophilia B (M. Roman et al, 1992, Somat. Cell. MoI. Genet. 18:247 58; S. N. Yao et al, 1994, Gen. Ther. 1:99 107; J. M. Wang et al, 1997, Blood 90:1075 82; G. Hortelano et al, 1999, Hum. Gene Ther.
• Myoblasts have also been used to treat muscle tissue damage or disease, as disclosed in U.S. Pat. No. 5,130,141 to Law et al, U.S. Pat. No. 5,538,722 to Blau et al, and application U.S. Patent No. 6,866,842 by Chancellor et al incorporated by reference herein.
• myoblast transplantation has been employed for the repair of myocardial dysfunction (C. E. Murry et al, 1996, J. Clin. Invest. 98:2512 23; B. Z. Atkins et al, 1999, Ann. Thorac. Surg. 67: 124 129; B. Z. Atkins et al, 1999, J. Heart Lung Transplant. 18:1173 80).
• U.S. Pat. No. 5,667,778 to Atala discloses the use of myoblasts suspended in a liquid polymer, such as alginate.
• the polymer solution acts as a matrix to prevent the myoblasts from migrating and/or undergoing phagocytosis after injection.
• the polymer solution presents the same problems as the biopolymers discussed above.
• the Atala patent is limited to uses of myoblasts in only muscle tissue, but no other tissue.
• the muscle-derived progenitor cell (MDC)-containing compositions of the present invention are provided as improved and novel materials for augmenting skeletal muscle. Further provided are methods of producing muscle-derived progenitor cell compositions that show long-term survival following transplantation, and methods of utilizing MDCs and compositions containing MDCs to treat various aesthetic and/or functional defects, including, but not limited to, skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.
• MDCs and compositions containing MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass. It is notable that prior attempts to use myoblasts for non-muscle tissue augmentation were unsuccessful (U.S. Pat. No. 5,667,778 to Atala). Therefore, the findings disclosed herein are unexpected, as they show that the muscle-derived progenitor cells according to the present invention can be successfully transplanted into non-muscle tissue, including skeletal muscle tissue, and exhibit long-term survival. As a result, MDCs and compositions comprising MDCs can be used as a general augmentation material for skeletal muscle production.
• the muscle-derived progenitor cells and compositions of the present invention can be derived from autologous sources, they carry a reduced risk of immunological complications in the host, including the reabsorption of augmentation materials, and the inflammation and/or scarring of the tissues surrounding the implant site.
• mesenchymal stem cells can be found in various connective tissues of the body including muscle, skeletal muscle, cartilage, etc. (H. E. Young et al., 1993, In vitro Cell Dev. Biol. 29A:723 736; H. E. Young, et al, 1995, Dev. Dynam.
• mesenchymal has been used historically to refer to a class of stem cells purified from skeletal muscle marrow, and not from muscle.
• mesenchymal stem cells are distinguished from the muscle-derived progenitor cells of the present invention.
• mesenchymal cells do not express the CD34 cell marker (M. F. Pittenger et al, 1999, Science 284:143 147), which is expressed by the muscle-derived progenitor cells described herein.
• MDCs muscle-derived progenitor cells
• MDC compositions containing the MDCs comprise early progenitor muscle cells, i.e., muscle-derived stem cells that express progenitor cell markers, including, but not limited to desmin, M-cadherin, MyoD, myogenin, CD34, and Bcl-2.
• progenitor cell markers including, but not limited to desmin, M-cadherin, MyoD, myogenin, CD34, and Bcl-2.
• these early progenitor muscle cells express the FIk-I, Sca-1, MNF, and c- met cell markers, but do not express the CD45 or c-Kit cell markers.
• the MDC population according to the present invention is particularly enriched with cells that express progenitor cell markers, including, but not limited to desmin, M-cadherin, MyoD, myogenin, CD34, and Bcl-2. This MDC population also expresses the FIk-I, Sca-1, MNF, and c-met cell markers, but does not express the CD45 or c-Kit cell markers.
• Such methods include the administration of MDC compositions by introduction into skeletal muscle, for example by direct injection into or on the surface of the tissue, or by systemic distribution of the compositions.
• MDCs and compositions comprising MDCs that are modified through the use of chemicals, growth media, and/or genetic manipulation.
• Such MDCs and compositions thereof comprise chemically or genetically modified cells useful for the production and delivery of biological compounds, and the treatment of various diseases, conditions, injuries, or illnesses.
• MDCs and compositions comprising MDCs that are modified through the use of chemicals, growth media, and/or genetic manipulation.
• Such MDCs and compositions thereof comprise chemically or genetically modified cells useful for the production and delivery of biological compounds, and the treatment of various diseases, conditions, injuries, or illnesses.
• compositions comprising MDCs and compositions comprising MDCs.
• These pharmaceutical compositions comprise isolated MDCs. These MDCs may be subsequently expanded by cell culture after isolation. In one aspect of this embodiment, these MDCs are frozen prior to delivery to a subject in need of the pharmaceutical composition.
• the invention also provides compositions and methods involving the isolation of MDCs using a single plating technique.
• MDCs are isolated from a biopsy of skeletal muscle.
• the skeletal muscle from the biopsy may be stored for 1-6 days.
• the skeletal muscle from the biopsy is stored at 4 °C.
• the cells are minced, and digested using a collagenase, dispase, another enzyme or a combination of enzymes. After washing the enzyme from the cells, the cells are cultured in a flask in culture medium for between about 30 and about 120 minutes. During this period of time, the "rapidly adhering cells" stick to the walls of the flask or container, while the “slowly adhering cells” or MDCs remain in suspension.
• the “slowly adhering cells” are transferred to a second flask or container and cultured therein for a period of 1-3 days. During this second period of time the "slowly adhering cells” or MDCs stick to the walls of the second flask or container.
• these MDCs are expanded to any number of cells.
• the cells are expanded in new culture media for between about 10 and 20 days. More preferably, the cells are expanded for 17 days.
• the MDCs, whether expanded or not expanded may be preserved in order to be transported or stored for a period of time before use.
• the MDCs are frozen. Preferably, the MDCs are frozen at between about -20 and -90 0 C. More preferably, the MDCs are frozen at about -80 0 C. These frozen MDCs are used as a pharmaceutical composition.
• MDCs whether frozen or preserved as a pharmaceutical composition, or used fresh, may be used to treat a number of skeletal muscle degenerative pathologies. These conditions include but are not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. MDCs, whether frozen or preserved as a pharmaceutical composition, or used fresh, may also be used for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass. Additional objects and advantages afforded by the present invention will be apparent from the detailed description and exemplification herein below.
• Figures IA and IB show micrographs of human MDCs (hMDCs) injected into mouse muscle with human dystrophin and mouse Y-chromosome stained to show chimerism in the human and mouse muscle cells that have fused.
• Figure 2 is a bar graph showing the percentage of dystrophin positive fibers in mice injected with hMDCs.
• the invention provides human MDCs and methods of using such cells to generate skeletal muscle tissue to repair damaged skeletal muscle or to increase skeletal muscle volume and/or strength to above wild type levels.
• the invention further provides methods of treating skeletal muscle disorders including but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.
• the isolation of human muscle-derived cells (MDCs) from adult tissue are capable of achieving increased skeletal muscle density and skeletal muscle volume within human subjects administered these cells.
• the present invention provides MDCs comprised of early progenitor cells (also termed muscle-derived progenitor cells or muscle-derived stem cells herein) that show long- term survival rates following transplantation into body tissues, preferably skeletal muscle.
• a muscle explant preferably skeletal muscle, is obtained from an animal donor, preferably from a mammal, including humans. This explant serves as a structural and functional syncytium including "rests" of muscle precursor cells (T. A. Partridge et al., 1978, Nature 73:306 8; B. H. Lipton et al, 1979, Science 205:12924).
• Cells isolated from primary muscle tissue contain mixture of fibroblasts, myoblasts, adipocytes, hematopoietic, and muscle-derived progenitor cells.
• the progenitor cells of a muscle-derived population can be enriched using differential adherence characteristics of primary muscle cells on collagen coated tissue flasks, such as described in U.S. Pat. No. 6,866,842 of Chancellor et al, incorporated herein by reference. Cells that are slow to adhere tend to be morphologically round, express high levels of desmin, and have the ability to fuse and differentiate into multinucleated myotubes U.S. Pat. No. 6,866,842 of Chancellor et al.).
• a preplating procedure may be used to differentiate rapidly adhering cells from slowly adhering cells (MDCs).
• MDCs slowly adhering cells
• populations of rapidly adhering MDC (PPl -4) and slowly adhering, round MDC (PP6) were isolated and enriched from skeletal muscle explants and tested for the expression of various markers using immunohistochemistry to determine the presence of pluripotent cells among the slowly adhering cells (Example 1; patent application U.S. Patent No. 6,866,842 to Chancellor et al.).
• the PP6 cells expressed myogenic markers, including desmin, MyoD, and Myogenin.
• the PP6 cells also expressed c-met and MNF, two genes that are expressed at an early stage of myogenesis (J. B. Miller et al, 1999, Curr. Top. Dev. Biol. 43:191 219; see Table 3).
• the PP6 showed a lower percentage of cells expressing M-cadherin, a satellite cell-specific marker (A. Irintchev et al., 1994, Development Dynamics 199:326 337), but a higher percentage of cells expressing Bcl-2, a marker limited to cells in the early stages of myogenesis (J. A. Dominov et al, 1998, J. Cell Biol. 142:537 544).
• the PP6 cells also expressed CD34, a marker identified with human hematopoietic progenitor cells, as well as stromal cell precursors in skeletal muscle marrow (R. G. Andrews et al, 1986, Blood 67:842 845; C. I. Civin et al, 1984, J. Immunol. 133:157 165; L. Fina et al, 1990, Blood 75:2417 2426; P. J. Simmons et al, 1991, Blood 78:2848 2853; see Table 3).
• the PP6 cells also expressed FIk-I, a mouse homologue of human KDR gene which was recently identified as a marker of hematopoietic cells with stem cell-like characteristics (B. L.
• the PP6 cells expressed Sca-1, a marker present in hematopoietic cells with stem cell-like characteristics (M. van de Rijn et al, 1989, Proc. Natl. Acad. Sci. USA 86:4634 8; M. Osawa et al., 1996, J. Immunol. 156:3207 14; see Table 3).
• the PP6 cells did not express the CD45 or c-Kit hematopoietic stem cell markers (reviewed in L K. Ashman, 1999, Int. J. Biochem. Cell. Biol. 31: 1037 51; G. A.
• the PP6 population of muscle-derived progenitor cells having the characteristics described herein are provided. These muscle- derived progenitor cells express the desmin, CD34, and Bcl-2 cell markers.
• the PP6 cells are isolated by the techniques described herein (Example 1) to obtain a population of muscle-derived progenitor cells that have long-term survivability following transplantation.
• the PP6 muscle-derived progenitor cell population comprises a significant percentage of cells that express progenitor cell markers, including, but not limited to desmin, CD34, and Bcl-2.
• PP6 cells express the FIk-I and Sca-1 cell markers, but do not express the CD45 or c-Kit markers.
• PP6 cells express the desmin, Sca-1, and FIk-I markers, but do not express the CD45 or c-Kit markers. It is preferred that the PP6 cells are utilized within about 1 day or about 24 hours after the last plating.
• the rapidly adhering cells and slowly adhering cells are separated from each other using a single plating technique.
• a single plating technique is described in Example 2.
• cells are provided from a skeletal muscle biopsy. The biopsy need only contain about 100 mg of cells. Biopsies ranging in size from about 50 mg to about 500 mg are used according to both the pre-plating and single plating methods of the invention. Further biopsies of 50, 100, 110, 120, 130, 140, 150, 200, 250, 300, 400 and 500 mg are used according to both the pre-plating and single plating methods of the invention.
• the tissue from the biopsy is then stored for 1 to 7 days.
• This storage is at a temperature from about room temperature to about 4 0 C.
• This waiting period causes the biopsied skeletal muscle tissue to undergo stress. While this stress is not necessary for the isolation of MDCs using this single plate technique, using the wait period generally results in a greater yield of MDCs.
• tissue from the biopsies is minced and centrifuged.
• the pellet is resuspended and digested using a digestion enzyme.
• Enzymes that may be used include, but are not limited to, collagenase, dispase or combinations of these enzymes.
• the enzyme is washed off of the cells.
• the cells are transferred to a flask in culture media for the isolation of the rapidly adhering cells.
• Many culture media may be used.
• Particularly preferred culture media include those that are designed for culture of endothelial cells including Cambrex Endothelial Growth Medium.
• This medium may be supplemented with other components including fetal bovine serum, IGF-I, bFGF, VEGF, EGF, hydrocortisone, heparin, and/or ascorbic acid.
• Other media that may be used in the single plating technique include InCeIl M310F medium. This medium may be supplemented as described above, or used unsupplemented.
• the step for isolation of the rapidly adhering cells may require culture in flask for a period of time from about 30 to about 120 minutes.
• the rapidly adhering cells adhere to the flask in 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes. After they adhere, the slowly adhering cells are separated from the rapidly adhering cells from removing the culture media from the flask to which the rapidly adhering cells are attached to.
• the culture medium removed from this flask is then transferred to a second flask.
• the cells may be centrifuged and resuspended in culture medium before being transferred to the second flask.
• the cells are cultured in this second flask for between 1 and 3 days. Preferably, the cells are cultured for two days.
• the slowly adhering cells adhere to the flask.
• the culture media is removed and new culture media is added in order to promote expansion of the MDCs.
• the MDCs may be expanded in number by culturing them for from about 10 to about 20 days.
• the MDCs may be expanded in number by culturing them for 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 days.
• the MDCs are subject to expansion culture for 17 days.
• the MDCs of the present invention can be isolated by fluorescence-activated cell sorting (FACS) analysis using labeled antibodies against one or more of the cell surface markers expressed by the MDCs (C. Webster et al, 1988, Exp. Cell. Res. 174:252 65; J. R. Blanton et ai, 1999, Muscle Nerve 22:43 50).
• FACS fluorescence-activated cell sorting
• FACS analysis can be performed using labeled antibodies that specifically bind to CD34, FIk-I, Sca-1, and/or the other cell-surface markers described herein to select a population of PP6-like cells that exhibit long-term survivability when introduced into the host tissue.
• fluorescence-detection labels for example, fluorescein or rhodamine, for antibody detection of different cell marker proteins.
• the isolated MDCs may be frozen to a temperature ranging from about -25 to about -90 0 C.
• the MDCs are frozen at about -80 0 C on dry ice for delayed use or transport.
• the freezing may be done with any cryopreservation medium known in the art.
• the MDCs are isolated from a skeletal muscle source and introduced or transplanted into a muscle or non-muscle soft tissue site of interest, or into skeletal muscle.
• the MDCs of the present invention are isolated and enriched to contain a large number of progenitor cells showing long-term survival following transplantation.
• the muscle-derived progenitor cells of this invention express a number of characteristic cell markers, such desmin, CD34, and Bcl-2.
• the muscle-derived progenitor cells of this invention express the Sca-1, and FIk- 1 cell markers, but do not express the CD45 or c-Kit cell markers (see Example 1).
• MDCs and compositions comprising MDCs of the present invention can be used to repair, treat, or ameliorate various aesthetic or functional conditions (e.g. defects) through the augmentation of skeletal muscle.
• such compositions can be used for the treatment of skeletal muscle disorders.
• Multiple and successive administrations of MDC are also embraced by the present invention.
• a skeletal muscle explant is preferably obtained from an autologous or heterologous human or animal source.
• An autologous animal or human source is more preferred.
• MDC compositions are then prepared and isolated as described herein.
• a suspension of mononucleated muscle cells is prepared. Such suspensions contain concentrations of the muscle-derived progenitor cells of the invention in a physiologically-acceptable carrier, excipient, or diluent.
• suspensions of MDC for administering to a subject can comprise 10 8 to 10 9 cells/ml in a sterile solution of complete medium modified to contain the subject's serum, as an alternative to fetal bovine serum.
• MDC suspensions can be in serum-free, sterile solutions, such as cryopreservation solutions (Celox Laboratories, St. Paul, Minn.). The MDC suspensions can then be introduced e.g., via injection, into one or more sites of the donor tissue.
• the described cells can be administered as a pharmaceutically or physiologically acceptable preparation or composition containing a physiologically acceptable carrier, excipient, or diluent, and administered to the tissues of the recipient organism of interest, including humans and non-human animals.
• the MDC-containing composition can be prepared by resuspending the cells in a suitable liquid or solution such as sterile physiological saline or other physiologically acceptable injectable aqueous liquids.
• suitable liquid or solution such as sterile physiological saline or other physiologically acceptable injectable aqueous liquids.
• the amounts of the components to be used in such compositions can be routinely determined by those having skill in the art.
• the MDCs or compositions thereof can be administered by placement of the MDC suspensions onto absorbent or adherent material, e.g., a collagen sponge matrix, and insertion of the MDC-containing material into or onto the site of interest.
• the MDCs can be administered by parenteral routes of injection, including subcutaneous, intravenous, intramuscular, and intrasternal.
• parenteral routes of injection including subcutaneous, intravenous, intramuscular, and intrasternal.
• Other modes of administration include, but are not limited to, intranasal, intrathecal, intracutaneous, percutaneous, enteral, and sublingual.
• administration of the MDCs can be mediated by endoscopic surgery.
• the composition is in sterile solution or suspension or can be resuspended in pharmaceutically- and physiologically-acceptable aqueous or oleaginous vehicles, which may contain preservatives, stabilizers, and material for rendering the solution or suspension isotonic with body fluids (i.e. blood) of the recipient.
• excipients suitable for use include water, phosphate buffered saline, pH 7.4, 0.15 M aqueous sodium chloride solution, dextrose, glycerol, dilute ethanol, and the like, and mixtures thereof.
• Illustrative stabilizers are polyethylene glycol, proteins, saccharides, amino acids, inorganic acids, and organic acids, which may be used either on their own or as admixtures.
• the amounts or quantities, as well as the routes of administration used, are determined on an individual basis, and correspond to the amounts used in similar types of applications or indications known to those of skill in the art.
• the closest possible immunological match between donor and recipient is desired. If an autologous source is not available, donor and recipient Class I and Class II histocompatibility antigens can be analyzed to determine the closest match available. This minimizes or eliminates immune rejection and reduces the need for immunosuppressive or immunomodulatory therapy. If required, immunosuppressive or immunomodulatory therapy can be started before, during, and/or after the transplant procedure. For example, cyclosporin A or other immunosuppressive drugs can be administered to the transplant recipient. Immunological tolerance may also be induced prior to transplantation by alternative methods known in the art (D. J. Watt et al., 1984, Clin. Exp. Immunol. 55:419; D.
• the MDCs can be administered to body tissues, including skeletal muscle.
• the number of cells in an MDC suspension and the mode of administration may vary depending on the site and condition being treated. From about 1.OxIO 5 to about IxIO 8 MDCs may be administered according to the invention.
• about 0.5-2.OxIO 6 MDCs are administered via a collagen sponge matrix for the treatment of an approximately 5 mm region of skull defect (see Example 3).
• the MDCs are prepared as described above and are administered, e.g. via injection, onto, into or around skeletal muscle tissue to provide additional skeletal muscle strength and/or volume.
• the number of MDC introduced is modulated to provide varying amounts of skeletal muscle density and/or skeletal muscle volume, as needed or required.
• the present invention also embraces the use of MDC of the invention in treating skeletal muscle disorders or enhancing skeletal muscle density and/or skeletal muscle volume.
• Skeletal muscle disorders include but are not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.
• the invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
• the MDCs of this invention may be genetically engineered to contain a nucleic acid sequence(s) encoding one or more active biomolecules, and to express these biomolecules, including proteins, polypeptides, peptides, hormones, metabolites, drugs, enzymes, and the like.
• Such MDCs may be histocompatible (autologous) or nonhistocompatible (allogeneic) to the recipient, including humans.
• These cells can serve as long-term local delivery systems for a variety of treatments, for example, for the treatment of skeletal muscle diseases and pathologies, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.
• the MDC used for cell-mediated gene transfer or delivery will desirably be matched vis-a-vis the major histocompatibility locus (MHC or HLA in humans).
• MHC or HLA matched cells may be autologous.
• the cells may be from a person having the same or a similar MHC or HLA antigen profile.
• the patient may also be tolerized to the allogeneic MHC antigens.
• the present invention also encompasses the use of cells lacking MHC Class I and/or II antigens, such as described in U.S. Pat. No. 5,538,722, incorporated herein by reference.
• the MDCs may be genetically engineered by a variety of molecular techniques and methods known to those having skill in the art, for example, transfection, infection, or transduction.
• Transduction as used herein commonly refers to cells that have been genetically engineered to contain a foreign or heterologous gene via the introduction of a viral or non-viral vector into the cells.
• Transfection more commonly refers to cells that have been genetically engineered to contain a foreign gene harbored in a plasmid, or non- viral vector.
• MDCs can be transfected or transduced by different vectors and thus can serve as gene delivery vehicles to transfer the expressed products into muscle.
• viral vectors are preferred, those having skill in the art will appreciate that the genetic engineering of cells to contain nucleic acid sequences encoding desired proteins or polypeptides, cytokines, and the like, may be carried out by methods known in the art, for example, as described in U.S. Pat. No. 5,538,722, including fusion, transfection, lipofection mediated by the use of liposomes, electroporation, precipitation with DEAE-Dextran or calcium phosphate, particle bombardment (biolistics) with nucleic acid-coated particles (e.g., gold particles), microinjection, and the like.
• nucleic acid-coated particles e.g., gold particles
• Vectors for introducing heterologous (i.e., foreign) nucleic acid (DNA or RNA) into muscle cells for the expression of bioactive products are well known in the art.
• Such vectors possess a promoter sequence, preferably, a promoter that is cell-specific and placed upstream of the sequence to be expressed.
• the vectors may also contain, optionally, one or more expressible marker genes for expression as an indication of successful transfection and expression of the nucleic acid sequences contained in the vector.
• Illustrative examples of vehicles or vector constructs for transfection or infection of the muscle-derived cells of the present invention include replication-defective viral vectors, DNA virus or RNA virus (retrovirus) vectors, including, but not limited to adenovirus, herpes simplex virus and adeno-associated viral vectors.
• Adeno-associated virus vectors are single stranded and allow the efficient delivery of multiple copies of nucleic acid to the cell's nucleus.
• the vectors will normally be substantially free of any prokaryotic DNA and may comprise a number of different functional nucleic acid sequences.
• polynucleotide e.g., DNA or RNA
• sequences comprising transcriptional and translational initiation and termination regulatory sequences including promoters (e.g., strong promoters, inducible promoters, and the like) and enhancers which are active in muscle cells.
• promoters e.g., strong promoters, inducible promoters, and the like
• enhancers which are active in muscle cells.
• an open reading frame (polynucleotide sequence) encoding a protein of interest; flanking sequences may also be included for site-directed integration.
• flanking sequences may also be included for site-directed integration.
• the 5'-flanking sequence will allow homologous recombination, thus changing the nature of the transcriptional initiation region, so as to provide for inducible or noninducible transcription to increase or decrease the level of transcription, as an example.
• the nucleic acid sequence desired to be expressed by the muscle-derived progenitor cell is that of a structural gene, or a functional fragment, segment or portion of the gene, that is heterologous to the muscle-derived progenitor cell and encodes a desired protein or polypeptide product, for example.
• the encoded and expressed product may be intracellular, i.e., retained in the cytoplasm, nucleus, or an organelle of a cell, or may be secreted by the cell.
• the natural signal sequence present in the structural gene may be retained, or a signal sequence that is not naturally present in the structural gene may be used.
• genes of interest for use in accordance with the present invention include genes encoding cell growth factors, cell differentiation factors, cell signaling factors and programmed cell death factors. Specific examples include, but are not limited to, genes encoding BMP-2 (rhBMP-2), IL-IRa, Factor IX, and connexin 43.
• a marker may be present for selection of cells containing the vector construct.
• the marker may be an inducible or non-inducible gene and will generally allow for positive selection under induction, or without induction, respectively.
• Examples of commonly-used marker genes include neomycin, dihydrofolate reductase, glutamine synthetase, and the like.
• the vector employed will generally also include an origin of replication and other genes that are necessary for replication in the host cells, as routinely employed by those having skill in the art.
• the replication system comprising the origin of replication and any proteins associated with replication encoded by a particular virus may be included as part of the construct.
• the replication system must be selected so that the genes encoding products necessary for replication do not ultimately transform the muscle-derived cells.
• Such replication systems are represented by replication-defective adenovirus constructed as described, for example, by G. Acsadi et ah, 1994, Hum. MoI. Genet 3:579 584, and by Epstein-Barr virus.
• replication defective vectors particularly, retroviral vectors that are replication defective
• BAG described by Price et al., 1987, Proc. Natl. Acad. Sci. USA, 84:156; and Sanes et ai, 1986, EMBO J., 5:3133.
• the final gene construct may contain one or more genes of interest, for example, a gene encoding a bioactive metabolic molecule.
• cDNA, synthetically produced DNA or chromosomal DNA may be employed utilizing methods and protocols known and practiced by those having skill in the art.
• infectious replication-defective viral vectors may be used to genetically engineer the cells prior to in vivo injection of the cells.
• the vectors may be introduced into retroviral producer cells for amphotrophic packaging. The natural expansion of muscle-derived progenitor cells into adjacent regions obviates a large number of injections into or at the site(s) of interest.
• the present invention provides ex vivo gene delivery to cells and tissues of a recipient mammalian host, including humans, through the use of MDC, e.g., early progenitor muscle cells, that have been virally transduced using an adenoviral vector engineered to contain a heterologous gene encoding a desired gene product.
• MDC e.g., early progenitor muscle cells
• an adenoviral vector engineered to contain a heterologous gene encoding a desired gene product e.g., early progenitor muscle cells
• the ex vivo procedure involves the use of the muscle-derived progenitor cells from isolated cells of muscle tissue.
• the muscle biopsy that will serve as the source of muscle-derived progenitor cells can be obtained from an injury site or from another area that may be more easily obtainable from the clinical surgeon.
• clonal isolates can be derived from the population of muscle-derived progenitor cells (i.e., PP6 cells or "slowly adhering" cells using the single plate procedure) using various procedures known in the art, for example, limiting dilution plating in tissue culture medium.
• Clonal isolates comprise genetically identical cells that originate from a single, solitary cell.
• clonal isolates can be derived using FACS analysis as described above, followed by limiting dilution to achieve a single cell per well to establish a clonally isolated cell line.
• An example of a clonal isolate derived from the PP6 cell population is me 13, which is described in Example 1.
• MDC clonal isolates are utilized in the present methods, as well as for genetic engineering for the expression of one or more bioactive molecules, or in gene replacement therapies.
• the MDCs are first infected with engineered viral vectors containing at least one heterologous gene encoding a desired gene product, suspended in a physiologically acceptable carrier or excipient, such as saline or phosphate buffered saline, and then administered to an appropriate site in the host.
• a physiologically acceptable carrier or excipient such as saline or phosphate buffered saline
• the MDCs can be administered to body tissues, including skeletal muscle, as described above.
• the desired gene product is expressed by the injected cells, which thus introduce the gene product into the host.
• the introduced and expressed gene products can thereby be utilized to treat, repair, or ameliorate the injury, dysfunction, or disease, due to their being expressed over long time periods by the MDCs of the invention, having long-term survival in the host.
• implantation of 10 6 myoblasts per 100 mg muscle was required for partial correction of muscle enzyme defects (see, J. E. Morgan et al, 1988, J. Neural. Sci. 86:137; T. A. Partridge et al, 1989, Nature 337:176).
• approximately 10 12 MDCs suspended in a physiologically compatible medium can be implanted into muscle tissue for gene therapy for a 70 kg human.
• This number of MDC of the invention can be produced from a single 100 mg skeletal muscle biopsy from a human source (see below).
• an injection of genetically engineered MDC into a given tissue or site of injury comprises a therapeutically effective amount of cells in solution or suspension, preferably, about 10 5 to 10 6 cells per cm 3 of tissue to be treated, in a physiologically acceptable medium.
• Example 1 MDC Enrichment, Isolation and Analysis According to the Pre-Plating Method. MDCs were prepared as described (U.S. Pat. No. 6,866,842 of Chancellor et al).
• Muscle explants were obtained from the hind limbs of a number of sources, namely from 3- week-old mdx (dystrophic) mice (C57BL/10ScSn mdx/mdx, Jackson Laboratories), 4-6 week-old normal female SD (Sprague Dawley) rats, or SCID (severe combined immunodeficiency) mice.
• the muscle tissue from each of the animal sources was dissected to remove any bones and minced into a slurry. The slurry was then digested by 1 hour serial incubations with 0.2% type XI collagenase, dispase (grade ⁇ , 240 unit), and 0.1% trypsin at 37 0 C.
• the resulting cell suspension was passed through 18, 20, and 22 gauge needles and centrifuged at 3000 rpm for 5 minutes. Subsequently, cells were suspended in growth medium (DMEM supplemented with 10% fetal bovine serum, 10% horse serum, 0.5% chick embryo extract, and 2% penicillin/streptomycin). Cells were then preplated in collagen- coated flasks (U.S. Pat. No. 6,866,842 of Chancellor et al.). After approximately 1 hour, the supernatant was removed from the flask and re-plated into a fresh collagen-coated flask. The cells which adhered rapidly within this 1 hour incubation were mostly fibroblasts (Z. Qu et al., supra; U.S. Pat. No.
• the mdx PPl -4, mdx PP6, normal PP6, and fibroblast cell populations were examined by immunohistochemical analysis for the expression of cell markers. The results of this analysis are shown in Table 1.
• Mdx PP1-4, mdx PP6, normal PP6, and fibroblast cells were derived by preplating technique and examined by immunohistochemical analysis.
• “-” indicates less than 2% of the cells showed expression;
• “-/+” indicates 5-50% of the cells showed expression;
• “+/-” indicates -40-80% of the cells showed expression;
• “+” indicates that >95% of the cells showed expression;
• “nor” indicates normal cells; "na” indicates that the immunohistochemical data is not available.
• MDCs were grown in proliferation medium containing DMEM (Dulbecco's Modified Eagle Medium) with 10% FBS (fetal bovine serum), 10% HS (horse serum), 0.5% chick embryo extract, and 1% penicillin/streptomycin, or fusion medium containing DMEM supplemented with 2% fetal bovine serum and 1% antibiotic solution. All media supplies were purchased through Gibco Laboratories (Grand Island, N.Y.).
• MDCs Populations of rapidly- and slowly-adhering MDCs were isolated from skeletal muscle of a mammalian subject.
• the subject may be a human, rat, dog or other mammal.
• Biopsy size ranged from 42 to 247 mg.
• Skeletal muscle biopsy tissue is immediately placed in cold hypothermic medium (HYPOTHERMOSOL® (BioLife) supplemented with gentamicin sulfate (100 ng/ml, Roche)) and stored at 4°C. After 3 to 7 days, biopsy tissue is removed from storage and production is initiated. Any connective or non-muscle tissue is dissected from the biopsy sample. The remaining muscle tissue that is used for isolation is weighed. The tissue is minced in Hank's Balanced Salt Solution (HBSS), transferred to a conical tube, and centrifuged (2,500xg, 5 minutes). The pellet is then resuspended in a Digestion Enzyme solution (Liberase Blendzyme 4 (0.4-1.0 U/mL, Roche)).
• HBSS Hank's Balanced Salt Solution
• Digestion Enzyme solution 2 mL of Digestion Enzyme solution is used per 100 mg of biopsy tissue and is incubated for 30 minutes at 37 0 C on a rotating plate. The sample is then centrifuged (2,500xg, 5 minutes). The pellet is resuspended in culture medium and passed through a 70 ⁇ m cell strainer.
• the culture media used for the procedures described in this Example was Cambrex Endothelial Growth Medium EGM-2 basal medium supplemented with the following components: i. 10% (v/v) fetal bovine serum, and ii.
• Cambrex EGM-2 SingleQuot Kit which contains: Insulin Growth Factor-1 (IGF-I), Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), Hydrocortisone, Heparin, and Ascorbic Acid.
• IGF-I Insulin Growth Factor-1
• bFGF Basic Fibroblast Growth Factor
• VEGF Vascular Endothelial Growth Factor
• EGF Epidermal Growth Factor
• Hydrocortisone Heparin
• Heparin Ascorbic Acid
• the cell culture supernatant is removed from the T25 flask and placed into a 15 mL conical tube.
• the T25 culture flask is rinsed with 2 mL of warmed culture medium and transferred to the aforementioned 15 mL conical tube.
• the 15 mL conical tube is centrifuged (2,500xg, 5 minutes). The pellet is resuspended in culture medium and transferred to a new T25 culture flask.
• the flask is incubated for ⁇ 2 days at 37°C in 5% CO2 (cells that attach to this flask are the "slowly-adhering cells"). After incubation, the cell culture supernatant is aspirated and new culture medium is added to the flask.
• the flask is then returned to the incubator for expansion.
• Standard culture passaging is carried out from here on to maintain the cell confluency in the culture flask at less than 50%.
• Trypsin-EDTA 0.25%, Invitrogen
• Typical expansion of the "slowly-adhering cells” takes an average of 17 days (starting from the day production is initiated) to achieve an average total viable cell number of 37 million cells.
• the cells are harvested from the flask using Trypsin-EDTA and centrifuged (2,500xg, 5 minutes). The pellet is resuspended in BSS-P solution (HBSS supplemented with human serum albumin (2% v/v, Sera Care Life)) and counted. The cell solution is then centrifuged again (2,500xg, 5 minutes), resuspended with Cryopreservation Medium (CryoStor (Biolife) supplemented with human serum albumin (2% v/v, Sera Care Life Sciences)) to the desired cell concentration, and packaged in the appropriate vial for cryogenic storage. The cryovial is placed into a freezing container and placed in the -80 0 C freezer. Cells are administered by thawing the frozen cell suspension at room temperature with an equal volume of physiologic saline and injected directly
• the lineage characterization of the slowly adhering cell populations shows: Myogenic (87.4% CD56+, 89.2% desmin+), Endothelial (0.0% CD31+), Hematopoietic (0.3% CD45+), and Fibroblast (6.8% CD90+/CD56-).
• cryopreservation medium 3 x 10 5 cells in 15 ⁇ l
• 15 ⁇ l of cryopreservation medium alone was placed into the tube.
• These tubes were stored at -80 0 C until injection.
• a tube was removed from storage, thawed at room temperature, and resuspended with 15 ⁇ l of 0.9% sodium chloride solution.
• the resulting 30 ⁇ l solution was then drawn into a 0.5 cc insulin syringe with a 30 gauge needle. The investigator performing the surgery and injection was blinded to the contents of the tubes.
• CD56 was measured by flow cytometry (Guava) using PE-conjugated anti-CD56 antibody (1:50, BD Pharmingen) and PE-conjugated isotype control monoclonal antibody (1:50, BD Pharmingen).
• Desmin was measured by flow cytometry (Guava) on paraformaldehyde-fixed cells (BD Pharmingen) using a monoclonal desmin antibody (1: 100, Dako) and an isotype control monoclonal antibody (1:200, BD Pharmingen).
• hMDCs human muscle derived cells
• Pre-Plate Technique This technique is disclosed throughout the application and specifically, above in Example 1.
• Isolation and Cell Culture Candidate populations were obtained using the pre-plate technique. These cells were grown in EGMTM-2 media (Cambrex) at a density of 600 cells/cm 2 and passaged every 72-96 hours before confluence under standard conditions (5.0% CO 2 , 37°C).
• Flow Cytometry hMDC were analyzed for the presence of the cell surface cluster of differentiation markers CD34, CD56, CD144, and CD146.
• Immunochemistry hMDC were stained for desmin, myosin heavy chain, and dystrophin.
• Bioinformatic Live Cell Imaging Cells were grown in a cell culture system with dynamic imaging. Images were taken at 10-min. intervals. We measured numerous parameters such as doubling rate, growth rate, total cell number, elongation, area, and perimeter for the various populations at early passage and late passage. We compared human MDC phenotypic profiles among the different preplate fractions to identify both molecular and behavioral characteristics that might predict in vivo regeneration efficiency.
• preplate fractions - preplates 1 and 2 (ppl-2), preplates 2-3 (pp2-3) and preplates 5-6). All populations were negative for CD34 and CD 144, and positive for CD56 and CD146. Over time, a decrease in CD56 and CD146 was observed. Imunostaining revealed the myogenic potential of the cells, as they displayed the ability to fuse into multinucleated myotubes, and showed desmin, myosin, and dystrophin expression.
• Time-elapsed imaging showed much variability in parameters such as cellular division time, population doubling time, cellular motility behavior, and morphological parameters.
• Cells grown in EGM2 showed a decrease in proliferation rates as cells were expanded.
• Our analysis to date has no shown any differences in these behaviors which are related to preplate fraction.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• General Health & Medical Sciences (AREA)
• Zoology (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Cell Biology (AREA)
• Wood Science & Technology (AREA)
• Physical Education & Sports Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Developmental Biology & Embryology (AREA)
• General Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Cardiology (AREA)
• Immunology (AREA)
• Endocrinology (AREA)
• Virology (AREA)
• Pain & Pain Management (AREA)
• Vascular Medicine (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Materials For Medical Uses (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=40526882

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Family Cites Families (8)

• 2008
  • 2008-10-03 CA CA2701354A patent/CA2701354C/fr active Active
  • 2008-10-03 WO PCT/US2008/011458 patent/WO2009045506A2/fr active Application Filing
  • 2008-10-03 JP JP2010527998A patent/JP5687059B2/ja active Active
  • 2008-10-03 EP EP08836519.2A patent/EP2209482A4/fr active Pending
  • 2008-10-03 AU AU2008307519A patent/AU2008307519B9/en active Active
• 2013
  • 2013-12-02 JP JP2013249167A patent/JP2014040485A/ja not_active Withdrawn

Also Published As

Similar Documents

Legal Events